Conexeu Completed 12-Month Preclinical P.R.O.O.F Research, Supporting Its Planned Move Into the $11 Billion Medical Aesthetics Market as a Platform.

Conexeu Sciences Inc., a preclinical-stage biotech organization developing a tissue-restoration platform, announced the conclusion of the P.R.O.O.F phase (Performance and Regeneration Outcomes of Flowable Collagen) of the preclinical package for its CXU platform. The completed phase offers the evidence base that the industry has been building to as it prepares for a focused first move into healthcare aesthetics.

“Our first regulatory step is a predicate-based 510(k) in wound care, which is intended to serve as the foundation for our planned move into aesthetics,” said Miles Harrison, President and CEO of Conexeu Sciences. “GLP-1 is unique among the crucial healthcare stories of a generation. Its achievement has created a completely novel patient profile: patients whose bodies have transformed more rapidly than the aesthetics sector was built to address. We believe no existing injectable was intended precisely for that gap. This phase of our preclinical program provides us with an evidence base to remain advancing CXU toward new opportunities.”

The Catalyst: What P.R.O.O.F Means?

P.R.O.O.F, or Performance and Regeneration Outcomes of Flowable Collagen, is Conexeu’s 12-month preclinical research and an imperative landmark in the advancement of the CXU™ platform. It does not signify a profitable launch or governing clearance. Instead, it marks the point at which the organization has finished a preclinical evidence package designed to support its continued development toward healthcare aesthetics.

The Three Evidence Pillars

Pillar One: Facial Tissue Restoration

In a small-volume facial application, the research saw its objectives in a cheek model, representative tissue restoration in the parameters recognized for the research.

Pillar Two: Large-Volume Tissue Restoration

In large-volume subcutaneous tissue, the research met its objectives in a 200cc-equivalent model, representing tissue repair at volumes relevant to strengthening future applications.

Pillar Three: Injectable Performance

The injectable aesthetics have already recognized the core performance features that a material is essential to meet. It should be injectable, which means it flows via a fine-gauge needle for exact placement. It also demonstrates volumizing performance, which means it maintains shape and fullness after placement. CXU met these predefined performance benchmarks.

The Milestone Behind the Move

The completed 12-month preclinical research measured tissue response to the CXU platform at many timepoints after intradermal and subcutaneous placement in an animal study. The research involves histologic assessment of scaffold perseverance, host-tissue response, tissue ingrowth, integration, vascularization, and remodelling.

This research involves two arms: a small-volume facemask arm observed in the full 12 months, and a higher-volume body arm intended to estimate performance in a higher-volume soft-tissue repair.

The organization intends to submit the output for scientific presentation and peer-reviewed publication. To preserve the integrity of that procedure, Conexeu is not revealing detailed findings, measurable analyses, or specific histologic endpoints at this time.

According to Towards Healthcare, the medical aesthetics market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 6.67 billion in 2026 to approximately USD 8.93 billion by 2035, representing a compound annual growth rate (CAGR) of 3.29% from 2026 to 2035, driven by increasing demand of medical aesthetics due to it spread beyond physical advancement to involves improved confidence, enhanced self-esteem, and improved overall quality of life.  The medicinal supervision inherent in these management ensures that obtain safe, efficient care from qualified professionals who understand together the art and science of aesthetic improvement.

About Conexeu Sciences Inc.

Conexeu Sciences is a preclinical-stage regenerative tissue platform organization. Our patented bioregenerative extracellular matrix (ECM) stand, CXU, is constructed on a single physical principle: one formula, one equipment, intended to scale in the multiple addressable sectors.

Conexeu is directing major, multi-billion-dollar end markets, involving wound care, periodontal uses, and facial and body tissue repair, involving the tissue variations that can follow GLP-1 weight loss, with further increasing advancement in 3D printing and bio fabrication workflows, and the veterinary sector. The organization is advancing a predicate-driven U.S. government approach with an expected 510(k) submission in early 2027 for its initial sign, subject to regulatory review.

The platform is stranded in more than a decade of university preclinical studies and protected by a multi-jurisdictional patent estate spanning over 40 jurisdictions, such as the U.S., EU, Japan, and Australia, with protection pending in Canada. Conexeu owns the platform IP, holding title, rights, and interest entirely, with no royalty or certifying obligations, and aims to expand into new indications and markets.

A recent report by Towards Healthcare highlights that the medical aesthetics market is witnessing growth because healthcare aesthetics remains an emerging field, with advanced technologies and treatment strategies constantly developing. Recent developments in laser technology, skin rejuvenation technology, and injectable products promise even more efficient treatments with lowered downtime and improved safety profiles. Targeted treatment strategies that depend on genetic testing and progressive skin analysis are becoming increasingly prevalent, enabling truly modified treatment plans.